Physician profile
Jere' Kitchen
NPI 1144365909
$5,361.69
in general payments reported to CMS, 2019-2025
39 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $894 · 2022: $638 · 2023: $1,186 · 2024: $1,423 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.34 | 2021-2025 | |
| Lilly USA, LLC | $861.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $669.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $489.01 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $362.38 | 2021-2025 | |
| Abbott Laboratories | $290.78 | 2021-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $196.10 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $150.05 | 2021 | |
| Merck Sharp & Dohme LLC | $116.60 | 2021-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Amgen INC. | $108.82 | 2021-2025 | Evenity, Prolia, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $103.07 | 2021-2022 | |
| Glaxosmithkline, LLC. | $101.35 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $89.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.29 | 2023-2025 | Jardiance, Tradjenta |
| Boston Scientific Corporation | $70.04 | 2022-2024 | Watchman Flx |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jere' Kitchen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.